Sarcopenic obesity assessed using dual energy X-ray absorptiometry (DXA) can predict cardiovascular disease in patients with type 2 diabetes: a retrospective observational study

Tatsuya Fukuda1, Ryotaro Bouchi1,2,3*, Takato Takeuchi1, Kazutaka Tsujimoto1, Isao Minami1, Takanobu Yoshimoto1 and Yoshihiro Ogawa4,5

Abstract

Background: Sarcopenic obesity, defined as reduced skeletal muscle mass and power with increased adiposity, was reported to be associated with cardiovascular disease risks in previous cross-sectional studies. Whole body dual-energy X-ray absorptiometry (DXA) can simultaneously evaluate both fat and muscle mass, therefore, whole body DXA may be suitable for the diagnosis of sarcopenic obesity. However, little is known regarding whether sarcopenic obesity determined using whole body DXA could predict incident cardiovascular disease (CVD). The aim of this study was to investigate the impact of sarcopenic obesity on incident CVD in patients with type 2 diabetes.

Methods: A total of 716 Japanese patients (mean age 65 ± 13 years; 47.0% female) were enrolled. Android fat mass (kg), gynoid fat mass (kg), and skeletal muscle index (SMI) calculated as appendicular non-fat mass (kg) divided by height squared (m²), were measured using whole body DXA. Sarcopenic obesity was defined as the coexistence of low SMI and obesity determined by four patterns of obesity as follows: android to gynoid ratio (A/G ratio), android fat mass or percentage of body fat (%BF) was higher than the sex-specific median, or body mass index (BMI) was equal to or greater than 25 kg/m². The study endpoint was the first occurrence or recurrence of CVD.

Results: Over a median follow up of 2.6 years (IQR 2.1–3.2 years), 53 patients reached the endpoint. Sarcopenic obesity was significantly associated with incident CVD even after adjustment for the confounding variables, when using A/G ratio [hazard ratio (HR) 2.63, 95% CI 1.10–6.28, p = 0.030] and android fat mass (HR 2.57, 95% CI 1.01–6.54, p = 0.048) to define obesity, but not %BF (HR 1.67, 95% CI 0.69–4.02, p = 0.252), and BMI (HR 1.55, 95% CI 0.44–5.49, p = 0.496).

Conclusions: The present data suggest that the whole body DXA is valuable in the diagnosis of sarcopenic obesity (high A/G ratio or android fat mass with low SMI) to determine the risk of CVD events in patients with type 2 diabetes. Meanwhile, sarcopenic obesity classified with low SMI, and high %BF or BMI was not associated with incident CVD.

Keywords: Sarcopenic obesity, Cardiovascular disease, Visceral adiposity, Type 2 diabetes, Dual-energy X-ray absorptiometry

*Correspondence: bouchi.mem@tmd.ac.jp
1 Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan
Full list of author information is available at the end of the article

© The Author(s) 2018. This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Background

Obesity is well known to be associated with various comorbidities such as type 2 diabetes, dyslipidemia, hypertension, and cardiovascular disease (CVD) [1]. In particular, visceral adiposity is reported to have greater impact on metabolic abnormalities [2], CVD [3], and mortality [4], compared with total adiposity as usually represented by body mass index (BMI). A recent large-scale prospective study revealed that visceral adiposity has been more useful to predict the risk of CVD than BMI in mostly non-diabetic subjects [5], and we showed that not BMI but visceral fat accumulation measured by dual bioelectrical impedance analyzer could predict incident CVD in patients with type 2 diabetes [6]. CVD is the leading cause of death in diabetic patients [7], therefore, accurate assessment of visceral fat accumulation is critical for assessing the risk of CVD, especially in patients with diabetes.

In addition to obesity, sarcopenia, defined as loss of skeletal muscle mass and strength with aging, has been reported to be associated with not only physical disability but also CVD. Ochi et al. [8] showed that sarcopenia is associated with increased arterial stiffness in middle-aged to elderly men, and Chin et al. [9] reported that sarcopenia was independently associated with the presence of CVD after adjusting for other cardiovascular risk factors in a large scale cross-sectional population-based study. Sarcopenia often co-occurs with obesity, the state called sarcopenic obesity, which contributes to significantly increased risks for physical disability and mobility impairment compared with sarcopenia or obesity alone [10, 11]. Furthermore, several cross-sectional studies demonstrated that individuals with sarcopenic obesity have a greater risk of hyperglycemia, hypertension, dyslipidemia, and insulin resistance than individuals without sarcopenic obesity [12–14]. Therefore, it is conceivable that individuals with sarcopenic obesity are at a high risk for incident CVD. Actually in the 5th Korean National Health and Nutrition Examination Survey, individuals with sarcopenic obesity defined by low muscle mass and high BMI had significantly high 10-year CVD risk determined using the Framingham risk model, whereas sarcopenic non-obese and non-sarcopenic obese individuals were not associated with an increased 10-year CVD risk [15]. However, there are very few observational studies that investigated the association between sarcopenic obesity evaluated based on direct measures of body fat and muscle mass, and incident CVD.

In recent years, visceral adiposity was reported to contribute to the progression of sarcopenia via physical inactivity, inflammatory cytokines such as interleukin-6 and tumor necrosis factor-α, and insulin resistance [16, 17]. Indeed, it is reported that patients with diabetes have an increased risk for the excessive loss of both skeletal muscle mass and strength in large scale longitudinal surveys [18, 19]. These findings presumably indicated that patients with diabetes have a higher risk of sarcopenic obesity, and sarcopenic obesity could partially account for the close relationship between diabetes and CVD. Nevertheless, little evidence was available to investigate the impact of sarcopenic obesity on incident CVD in patients with type 2 diabetes.

As for the direct measures of body fat distribution, computed tomography (CT) is considered the gold standard for abdominal fat quantification [20]. However, CT examination has some defects in clinical use, including exposure to radiation and high cost. Whole body dual-energy X-ray absorptiometry (DXA) can simultaneously evaluate both regional fat and muscle mass with much less radiation exposure than CT examination [21], and can accurately measure visceral fat as with CT examination [22]. Therefore, DXA may be suitable for the diagnosis of sarcopenic obesity. In addition, percentage of body fat (%BF) as indicator for total adiposity can be measured in the whole body DXA examination. Some previous studies were conducted using DXA often used %BF as obesity indicator in the examination of the association between sarcopenic obesity and cardiometabolic risks [11, 23, 24], however, few studies compared the predictive ability of each indicator for total and visceral adiposity obtained using the whole body DXA in examining the association between sarcopenic obesity and cardiometabolic risks or CVD.

Consequently, we carried out a retrospective observational study to examine whether sarcopenic obesity defined using the whole body DXA could predict incident CVD, and which indicator of obesity obtained from the whole body DXA is appropriate for diagnosis of sarcopenic obesity in prediction of CVD in patients with type 2 diabetes.

Methods

Subject

This retrospective, observational study included patients aged older than 20 years who regularly visited to Tokyo Medical and Dental University Hospital between 1 May 2008 and 31 October 2015. Patients were eligible if they were diagnosed with type 2 diabetes according to the criteria of the Japan Diabetes Society (JDS) [25], and underwent a whole body DXA during the study period. As shown in Fig. 1, 1866 patients had undergone a whole body DXA during the study period at our hospital, of whom 896 patients were diagnosed as type 2 diabetics. Exclusion criteria included renal impairment (estimated glomerular filtration rate (GFR) [eGFR]<15 ml/min/1.73 m² or undergoing renal replacement therapy),
pregnancy, infectious diseases, muscular dystrophy, lipodystrophy and cancer. Finally, this study included 716 patients (Fig. 1). This study complies with the principles laid by Declaration of Helsinki and has been approved by the ethical committee of Tokyo Medical and Dental University (No. M2017-260).

Clinical and biochemical analysis
Patient information about smoking status, medical history including the history of CVD, the severity of diabetic retinopathy, and medication were extracted from the medical records. Smoking was classified as non-smoker or current smoker. BMI was calculated based on the following formula: Bodyweight in kg divided by height in meters squared. Systolic and diastolic blood pressures (SBP and DBP) were measured after 5 min of seated rest, using an electronic sphygmomanometer (ES-H55, Terumo Inc., Tokyo, Japan). The measurement of HbA1c was performed using latex agglutination method. HbA1c values estimated as the JDS method was converted to the National Glycohemoglobin Standardization Program values [25]. GFR was estimated using the following equation for the Japanese, as proposed by the Japanese Society of Nephrology [26]; $GFR = 194 \times SCr^{-1.094} \times age^{-0.287}$ [if female] $\times 0.739$, where SCr stands for serum creatinine in mg/dl, measured using an enzymatic method. Urinary albumin and creatinine concentrations were measured using turbidimetric immunoassay and enzymatic method, and the urinary albumin-to-creatinine ratio (ACR, mg/g) was calculated for the assessment of albuminuria in a spot urine sample.

Body composition measuring by DXA
Body composition was measured using the whole body DXA (Lunar iDXA; GE Healthcare, Madison, Wisconsin, USA) by certified radiological technologists. The total fat mass and non-fat mass, percentage of body fat (%BF), and the fat masses of android and gynoid regions were measured as previously described [22, 27]. Skeletal muscle index (SMI) was calculated based on the following formula: Appendicular skeletal muscle mass (fat-free mass in the upper and lower extremities) in kg divided by height in meters squared. A/G ratio was the ratio of android divided by gynoid.

Definition of sarcopenia, obesity, and sarcopenic obesity
Sarcopenia was defined as SMI less than 7.0kg/m^2 (in men) or 5.4kg/m^2 (in women) according to the criteria for Asians [28]. Studies have shown important relationships between A/G ratio and CVD risks including glycemic, lipid and blood pressure control in healthy subjects [29, 30]. In addition, we previously reported that A/G ratio is significantly and strongly correlated with visceral fat area (VFA) measured by CT both in male and female, and have a similar ability to VFA in the prediction of CVD risks in patients with type 2 diabetes [22]. Therefore, A/G ratio could be a valuable indicator for visceral adiposity. In addition to A/G ratio, several indicators of obesity are obtained in a whole body DXA such as android fat mass, and %BF. To evaluate the predictive ability of the indicators of obesity for incident CVD, obesity in the present study was defined in four ways as follows: A/G ratio was higher than the sex-specific median value in the present cohort (>0.80 for men, >0.62 for women), android fat mass was higher than the sex-specific median in the present cohort (>2.16 kg for men, >1.95 kg for women), and %BF was higher than the sex-specific median in the present cohort (>31.8% for men, >38.8% for women), or BMI was equal to or greater than 25 kg/m^2 [31]. Participants were classified into four categories of body composition according to each indicator of obesity as follows; normal (participants without either sarcopenia or obesity), sarcopenia (with sarcopenia and without obesity), obesity (without sarcopenia and with obesity), and sarcopenic obesity (with both sarcopenia and obesity).

Definition of cardiovascular disease
Incident CVD was defined as stroke, unstable angina, myocardial infarction, percutaneous coronary intervention, coronary bypass grafting, revascularization for carotid artery disease, angioplasty or major amputation due to peripheral arterial disease (PAD) or CVD death. The study endpoint was the first occurrence or recurrence of incident CVD.

Statistical analysis
Statistical analysis was carried out using SPSS (version 21.0; IBM Corp, Armonk, New York, USA). Data
are presented as the mean ± standard deviation (SD), or the median and interquartile range (IQR) according to the data distribution. Chi square test or Fisher’s exact test were used to compare categorical variables, and ANOVA followed by Tukey’s test for the post hoc analyses was used to compare the quantitative variables among patients with the four categories of body composition (normal, sarcopenia, obesity, and sarcopenic obesity). The hazard ratios (HRs) for the study endpoint of the categories of body composition were estimated using Cox proportional hazard models with normal category as the reference. In the multivariate model, the following variables were incorporated to the Cox regression analysis with a stepwise procedure: age, gender, duration of diabetes, history of CVD, smoking status, SBP, DBP, log-transformed ACR, eGFR, prevalence of proliferative diabetic retinopathy (PDR), triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, HbA1c, aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (γ-GTP), uric acid (UA), and the use of insulin, sulfonureas, metformins, alpha-glucosidase inhibitors, glinides, thiazolidinediones (TZDs), dipeptidyl peptidase 4 (DPP4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptors agonists (GLP1-RAs), calcium channel blockers (CCBs), angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), alpha blockers, beta blockers, diuretics, statins, fibrates, ezetimibe, eicosapentaenoic acids (EPAs), UA lowering agents and anti-platelet agents at baseline. Next, we created another multivariate model in which gender was entered in addition to the covariates selected in the multivariate model because male sex is one of the important risk factors for incident CVD and there is a clear difference in the body composition between men and women (gender-adjusted multivariate model). In addition to A/G ratio, we further calculated HRs of sarcopenic obesity when android fat mass, %BF or BMI was used for the classification of obesity (Additional file 1: Table S1). Additional file 1: Table S1 shows the baseline characteristics when using android fat mass for the classification of obesity. Sarcopenia patients were older, and obesity patients were younger than normal patients. The proportion of men were significantly higher in both sarcopenia and sarcopenic obesity patients than normal and obesity patients. DBP and γ-GTP were higher and HDL cholesterol level was lower in both obesity and sarcopenic obesity patients than normal and sarcopenia patients. There were no significant differences in the frequency of receiving metformins, DPP4 inhibitors, ARBs, CCBs, Diuretics, statins and UA lowering agents among the four categories of body composition. The baseline characteristics and medications in the four categories of body composition classified according to each indicator of obesity other than A/G ratio are shown in Additional file 1: Tables S1–S6. Additional file 1: Table S1 shows the baseline characteristics when using android fat mass for the classification of obesity. Sarcopenia patients were older, and obesity patients were younger than normal patients. The proportion of men were significantly higher in both sarcopenia and sarcopenic obesity patients than normal and obesity patients. The duration of diabetes was significantly longer in sarcopenic obesity patients than that in patients of the other categories. Moreover, DBP, triglycerides, AST, ALT, γ-GTP and UA were significantly higher in obesity patients than in patients of the other categories. The HDL cholesterol level was lower in both obesity and sarcopenic obesity patients than normal and sarcopenia patients. There were no significant differences in the proportion of current smoker, history of CVD, SBP, log-transformed ACR, eGFR, prevalence of PDR, and Hba1c. Medications in the four categories of body composition, when using A/G ratio for the classification of obesity, were listed in Table 2. There were significant differences in the frequency of receiving metformins, DPP4 inhibitors, ARBs, CCBs, Diuretics, statins and UA lowering agents among the four categories of body composition.

The baseline characteristics and medications in the four categories of body composition were estimated using Cox proportional hazard models with normal category as the reference. In the multivariate model, the following variables were incorporated to the Cox regression analysis with a stepwise procedure: age, gender, duration of diabetes, history of CVD, smoking status, SBP, DBP, log-transformed ACR, eGFR, prevalence of proliferative diabetic retinopathy (PDR), triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, HbA1c, aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (γ-GTP), uric acid (UA), and the use of insulin, sulfonureas, metformins, alpha-glucosidase inhibitors, glinides, thiazolidinediones (TZDs), dipeptidyl peptidase 4 (DPP4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptors agonists (GLP1-RAs), calcium channel blockers (CCBs), angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), alpha blockers, beta blockers, diuretics, statins, fibrates, ezetimibe, eicosapentaenoic acids (EPAs), UA lowering agents and anti-platelet agents at baseline. Next, we created another multivariate model in which gender was entered in addition to the covariates selected in the multivariate model because male sex is one of the important risk factors for incident CVD and there is a clear difference in the body composition between men and women (gender-adjusted multivariate model). In addition to A/G ratio, we further calculated HRs of sarcopenic obesity when android fat mass, %BF or BMI was used for the classification of obesity, respectively. P-values less than 0.05 were considered to be statistically significant.

Results
Clinical characteristics of the study population
Among the participants, 187 (26.1%), 171 (23.9%), 275 (38.4%) and 83 (11.6%) patients were classified as normal, sarcopenia, obesity and sarcopenic obesity, respectively, and Table 1 shows the clinical characteristics at baseline in the four categories of body composition, when using A/G ratio for the classification of obesity. The age and the proportion of men were significantly higher in sarcopenia and sarcopenic obesity patients than normal and obesity patients. The duration of diabetes was significantly longer in sarcopenic obesity patients than that in patients of the other categories. Moreover, DBP, triglycerides, AST, ALT, γ-GTP and UA were significantly higher in obesity patients than in patients of the other categories. The HDL cholesterol level was lower in both obesity and sarcopenic obesity patients than normal and sarcopenia patients. There were no significant differences in the proportion of current smoker, history of CVD, SBP, log-transformed ACR, eGFR, prevalence of PDR, and Hba1c. Medications in the four categories of body composition, when using A/G ratio for the classification of obesity, were listed in Table 2. There were significant differences in the frequency of receiving metformins, DPP4 inhibitors, ARBs, CCBs, Diuretics, statins and UA lowering agents among the four categories of body composition. The baseline characteristics and medications in the four categories of body composition were estimated using Cox proportional hazard models with normal category as the reference. In the multivariate model, the following variables were incorporated to the Cox regression analysis with a stepwise procedure: age, gender, duration of diabetes, history of CVD, smoking status, SBP, DBP, log-transformed ACR, eGFR, prevalence of proliferative diabetic retinopathy (PDR), triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, HbA1c, aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (γ-GTP), uric acid (UA), and the use of insulin, sulfonureas, metformins, alpha-glucosidase inhibitors, glinides, thiazolidinediones (TZDs), dipeptidyl peptidase 4 (DPP4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptors agonists (GLP1-RAs), calcium channel blockers (CCBs), angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), alpha blockers, beta blockers, diuretics, statins, fibrates, ezetimibe, eicosapentaenoic acids (EPAs), UA lowering agents and anti-platelet agents at baseline. Next, we created another multivariate model in which gender was entered in addition to the covariates selected in the multivariate model because male sex is one of the important risk factors for incident CVD and there is a clear difference in the body composition between men and women (gender-adjusted multivariate model). In addition to A/G ratio, we further calculated HRs of sarcopenic obesity when android fat mass, %BF or BMI was used for the classification of obesity, respectively. P-values less than 0.05 were considered to be statistically significant.

Results
Clinical characteristics of the study population
Among the participants, 187 (26.1%), 171 (23.9%), 275 (38.4%) and 83 (11.6%) patients were classified as normal, sarcopenia, obesity and sarcopenic obesity, respectively, and Table 1 shows the clinical characteristics at baseline in the four categories of body composition, when using A/G ratio for the classification of obesity. The age and the proportion of men were significantly higher in sarcopenia and sarcopenic obesity patients than normal and obesity patients. The duration of diabetes was significantly longer in sarcopenic obesity patients than that in patients of the other categories. Moreover, DBP, triglycerides, AST, ALT, γ-GTP and UA were significantly higher in obesity patients than in patients of the other categories. The HDL cholesterol level was lower in both obesity and sarcopenic obesity patients than normal and sarcopenia patients. There were no significant differences in the proportion of current smoker, history of CVD, SBP, log-transformed ACR, eGFR, prevalence of PDR, and Hba1c. Medications in the four categories of body composition, when using A/G ratio for the classification of obesity, were listed in Table 2. There were significant differences in the frequency of receiving metformins, DPP4 inhibitors, ARBs, CCBs, Diuretics, statins and UA lowering agents among the four categories of body composition. The baseline characteristics and medications in the four categories of body composition were estimated using Cox proportional hazard models with normal category as the reference. In the multivariate model, the following variables were incorporated to the Cox regression analysis with a stepwise procedure: age, gender, duration of diabetes, history of CVD, smoking status, SBP, DBP, log-transformed ACR, eGFR, prevalence of proliferative diabetic retinopathy (PDR), triglycerides, high-density lipoprotein (HDL) cholesterol, low-density lipoprotein (LDL) cholesterol, HbA1c, aspartate transaminase (AST), alanine transaminase (ALT), gamma-glutamyl transpeptidase (γ-GTP), uric acid (UA), and the use of insulin, sulfonureas, metformins, alpha-glucosidase inhibitors, glinides, thiazolidinediones (TZDs), dipeptidyl peptidase 4 (DPP4) inhibitors, sodium-glucose cotransporter 2 (SGLT-2) inhibitors, glucagon-like peptide-1 receptors agonists (GLP1-RAs), calcium channel blockers (CCBs), angiotensin converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs), alpha blockers, beta blockers, diuretics, statins, fibrates, ezetimibe, eicosapentaenoic acids (EPAs), UA lowering agents and anti-platelet agents at baseline. Next, we created another multivariate model in which gender was entered in addition to the covariates selected in the multivariate model because male sex is one of the important risk factors for incident CVD and there is a clear difference in the body composition between men and women (gender-adjusted multivariate model). In addition to A/G ratio, we further calculated HRs of sarcopenic obesity when android fat mass, %BF or BMI was used for the classification of obesity, respectively. P-values less than 0.05 were considered to be statistically significant.
|                        | Normal (n = 187) | Sarcopenia (n = 171) | Obesity (n = 275) | Sarcopenic Obesity (n = 83) | p value* |
|------------------------|------------------|----------------------|-------------------|-----------------------------|----------|
| Age (years)            | 62 ± 14          | 69 ± 11†             | 63 ± 12           | 70 ± 10†                    | <0.001   |
| Gender (% male)        | 39.6             | 67.3                 | 46.5              | 75.9                        | <0.001   |
| Body fat (%)           | 33.7 ± 7.2       | 28.1 ± 7.9†          | 38.8 ± 6.4†       | 35.3 ± 5.3                  | <0.001   |
| Android fat mass (kg)  | 1.8 (1.4–2.3)    | 1.2 (0.8–1.6)†       | 2.8 (2.3–3.7)†    | 2.1 (2.1–3.5)†              | <0.001   |
| Gynoid fat mass (kg)   | 3.1 (2.6–3.7)    | 2.1 (1.6–2.7)†       | 3.4 (2.8–4.3)†    | 2.5 (2.5–4.0)†              | <0.001   |
| A/G ratio              | 0.57 ± 0.14      | 0.53 ± 0.17          | 0.86 ± 0.15†      | 0.87 ± 0.12†                | <0.001   |
| SMI (kg/m²)            | 6.86 ± 1.05      | 5.70 ± 0.88†         | 7.41 ± 1.15†      | 6.00 ± 0.79†                | <0.001   |
| Body mass index (kg/m²)| 25.3 ± 3.8       | 20.8 ± 2.9†          | 29.1 ± 3.3†       | 23.7 ± 3.0†                 | <0.001   |
| Duration of diabetes   | 10.2 ± 9.6       | 11.4 ± 10.9          | 10.7 ± 8.8        | 15.3 ± 13.1†                | 0.001    |
| History of CVD (%)     | 19               | 22                   | 21                | 33                          | 0.092    |
| Current smoker (%)     | 12               | 16                   | 11                | 22                          | 0.083    |
| SBP (mmHg)             | 131 ± 22         | 127 ± 18             | 133 ± 18          | 130 ± 19                    | 0.072    |
| DBP (mmHg)             | 77 ± 14          | 73 ± 12              | 78 ± 12†          | 76 ± 13                     | 0.001    |
| Log ACR (mg/gCr)       | 1.69 ± 0.76      | 1.76 ± 0.75          | 1.75 ± 0.78       | 1.85 ± 0.77                 | 0.497    |
| eGFR (ml/min/1.73 m²)  | 73.8 ± 22.2      | 75.5 ± 29.8          | 69.5 ± 22.7       | 70.2 ± 25.9                 | 0.054    |
| PDR (%)                | 9                | 7                    | 13                | 10                          | 0.197    |
| HbA1c (%)              | 8.2 ± 2.0        | 8.1 ± 2.1            | 8.3 ± 1.7         | 8.6 ± 1.8                   | 0.266    |
| HbA1c (mmol/mol)       | 66.2 ± 21.2      | 64.9 ± 22.3          | 67.6 ± 18.4       | 70.0 ± 20.0                 | 0.266    |
| Triglycerides (mmol/l) | 1.32 (0.85–1.80) | 1.12 (0.82–1.76)     | 1.56 (1.10–2.21)† | 1.29 (1.08–2.21)†           | <0.001   |
| HDL cholesterol (mmol/l)| 1.50 ± 0.50     | 1.59 ± 0.53          | 1.33 ± 0.34†      | 1.31 ± 0.41†                | <0.001   |
| LDL cholesterol (mmol/l)| 2.80 ± 0.94    | 2.74 ± 0.78          | 2.90 ± 0.82       | 2.89 ± 0.97                 | 0.233    |
| AST (U/l)              | 21 (17–27)       | 21 (18–27)           | 24 (19–33)†       | 21 (19–31)†                 | <0.001   |
| ALT (U/l)              | 19 (14–28)       | 17 (13–23)           | 25 (18–42)†       | 18 (16–38)†                 | <0.001   |
| γ-GTP (U/l)            | 25 (18–48)       | 30 (20–48)           | 34 (22–59)†       | 33 (22–59)                  | 0.001    |
| UA (μmol/l)            | 297 ± 90         | 287 ± 80             | 335 ± 86†         | 325 ± 90                    | <0.001   |

ACR, albumin-to-creatinine ratio; A/G, android to gynoid fat; ALT, alanine transaminase; AST, aspartate transaminase; CVD, cardiovascular disease; DBP, diastolic blood pressure; eGFR, estimated glomerular filtration ratio; GTP, glutamyl transpeptidase; HDL, high-density lipoprotein; LDL, low-density lipoprotein; PDR, proliferative diabetic retinopathy; SBP, systolic blood pressure; SMI, skeletal muscle index; UA, uric acid

* p value for difference among the four groups in percepts (Chi square test or Fisher's exact test) or means (ANOVA)
† p < 0.05 vs normal patients by Tukey's test

Table S4). Additional file 1: Table S5 shows the baseline characteristics when using BMI for the classification of obesity. The age and the proportion of men were significantly higher in both sarcopenia and sarcopenic obesity patients than normal and obesity patients. The duration of diabetes was significantly longer in sarcopenic obesity patients than that in patients of the other categories. SBP, DBP, triglycerides and UA were significantly higher, and HDL cholesterol level was lower in obesity patients than in patients of the other categories. ALT was higher in obesity and sarcopenic obesity patients than normal and sarcopenia patients. AST was higher in sarcopenic obesity patients than that in patients of the other categories. There were significant differences in the frequency of receiving metformins, TZDs, DPP4 inhibitors, ARBs, CCBs, Beta blockers, statins, UA lowering agents and anti-platelet agents among the four categories of body composition, when using BMI for the classification of obesity (Additional file 1: Table S6).

**Prediction ability for incident CVD of sarcopenic obesity assessed by both A/G ratio and SMI**

During the median follow-up period of 2.6 years (IQR 2.1–3.2 years), 53 patients reached the end-point including 16 events of stroke, 26 events of coronary artery disease, 3 events of carotid artery disease, 2 events of PAD and 6 events of CVD death. Table 3 shows HRs for the endpoint in the categories of body composition classified according to A/G ratio and SMI. In the univariate model, sarcopenic obesity was significantly associated with increased risk of CVD event, with a hazard ratio (HR) of 4.50 (95% CI 1.93–10.46, p = 0.006). The association between sarcopenic obesity and CVD event remained significant (HR 2.63, 95% CI 1.10–6.28, p = 0.030), even after the adjustment for covariates including HDL cholesterol (HR 0.90, 95% CI 0.94–0.99, p = 0.002), HbA1c (HR 1.28, 95% CI 1.09–1.49, p = 0.002), eGFR (HR 0.97, 95% CI 0.96–0.98, p < 0.001), the use of ACEIs or ARBs (HR 2.07, 95% CI 1.11–3.86, p = 0.022), the use of DPP4 inhibitors (HR 1.32, 95% CI 1.05–1.66, p = 0.022), and the use of statins (HR 1.38, 95% CI 1.09–1.75, p = 0.006).
inhibitors (HR 0.46, 95% CI 0.23–0.91, p = 0.025), and history of CVD (HR 2.58, 95% CI 1.57–5.18, p = 0.001) which were selected as significant covariates by stepwise procedure (multivariate model). In the gender-adjusted multivariate model, the association between sarcopenic obesity and the end-point was slightly attenuated after further adjustment for gender (HR 2.14, 95% CI 0.88–5.21, p = 0.093). On the other hand, sarcopenia (HR 1.43, 95% CI 0.58–3.52, p = 0.439 in univariate model, HR 1.88, 95% CI 0.75–4.74, p = 0.179 in multivariate model, and HR 1.46, 95% CI 0.57–3.74, p = 0.429 in gender-adjusted multivariate model), and Obesity (HR 1.56, 95% CI 0.71–3.43, p = 0.269 in univariate model, HR 0.98, 95% CI 0.44–2.21, p = 0.969 in multivariate model, and HR 0.94, 95% CI 0.42–2.10, p = 0.870 in gender-adjusted multivariate model) were consistently not significantly associated with CVD event in all models.

**Prediction ability for incident CVD of sarcopenic obesity classified according to the indicators of obesity other than A/G ratio and SMI**

Next, we created additional statistical models in which whether sarcopenic obesity could predict the endpoint in each case android fat mass, %BF or BMI were selected instead of A/G ratio for the classification of body composition. Figure 2 shows HRs for the endpoint in the categories of body composition classified according to the A/G ratio in univariate (Fig. 2a) and multivariate (Fig. 2b) models, android fat mass in univariate (Fig. 2c) and multivariate (Fig. 2d) models, %BF in univariate (Fig. 2e) and multivariate (Fig. 2f) models, or BMI in univariate (Fig. 2g) and multivariate (Fig. 2h) models. The multivariate models were adjusted for independent variables including HDL cholesterol, HbA1c, eGFR, the use of ACEIs or ARBs, the use of DPP4 inhibitors, and history of CVD, all of which were identified as significant predictors for the end point in each model by a stepwise procedure. Sarcopenic obesity classified according to A/G ratio (HR 2.63, 95% CI 1.10–6.28, p = 0.030) or android (HR 2.57, 95% CI 1.01–6.54, p = 0.048) was significantly associated with the endpoint, whereas sarcopenic obesity classified according to %BF (HR 1.67, 95% CI 0.69–4.02, p = 0.252) and BMI (HR 1.55, 95% CI 0.44–5.49, p = 0.496) was not significantly associated with the endpoint in the multivariate models.

---

Table 2  Medication at baseline in the four categories of body composition classified using A/G ratio

|                        | Normal (n = 187) | Sarcopenia (n = 171) | Obesity (n = 275) | Sarcopenic obesity (n = 83) | p value* |
|------------------------|------------------|----------------------|-------------------|-----------------------------|----------|
| Insulin (%)            | 34               | 39                   | 36                | 39                          | 0.756    |
| Sulfonylureas (%)      | 20               | 21                   | 24                | 21                          | 0.652    |
| Metformins (%)         | 24               | 15                   | 43                | 29                          | <0.001   |
| Alpha-GIs (%)          | 16               | 16                   | 10                | 12                          | 0.146    |
| Glinides (%)           | 5                | 4                    | 3                 | 5                           | 0.704    |
| TZDs (%)               | 9                | 3                    | 8                 | 5                           | 0.698    |
| DPP4 inhibitors (%)    | 27               | 30                   | 39                | 46                          | 0.005    |
| SGLT2 inhibitors (%)   | 1                | 0                    | 1                 | 1                           | 0.631    |
| GLP1-RAs (%)           | 2                | 2                    | 3                 | 5                           | 0.396    |
| ACEIs (%)              | 5                | 2                    | 3                 | 5                           | <0.001   |
| ARBs (%)               | 41               | 32                   | 56                | 50                          | <0.001   |
| CCBs (%)               | 32               | 28                   | 46                | 43                          | <0.001   |
| Alpha blockers (%)     | 1                | 1                    | 3                 | 0                           | 0.122    |
| Beta blockers (%)      | 11               | 8                    | 11                | 18                          | 0.129    |
| Diuretics (%)          | 10               | 10                   | 8                 | 12                          | 0.790    |
| Statins (%)            | 47               | 31                   | 54                | 40                          | <0.001   |
| Fibrates (%)           | 5                | 2                    | 2                 | 2                           | 0.103    |
| Ezetimib (%)           | 5                | 2                    | 2                 | 0                           | 0.082    |
| EPAs (%)               | 3                | 2                    | 3                 | 5                           | 0.774    |
| UA lowering agents (%) | 8                | 8                    | 15                | 13                          | 0.029    |
| Anti-platelet agents (%)| 18              | 22                   | 26                | 33                          | 0.050    |

ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CCBs, calcium channel blockers; DPP4, dipeptidyl peptidase 4; EPA, eicosapentaenoic acid; Gls, glycosidase inhibitors; GLP1-RA, glucagon-like peptide-1 receptors agonist; SGLT2, sodium-glucose cotransporter 2; TZDs, thiazolidinediones; UA, uric acid

* Chi square test or Fisher’s exact test
The present study firstly demonstrated that sarcopenic obesity assessed by the whole body DXA is an independent risk factor for CVD event in patients with type 2 diabetes, when using A/G ratio or android fat mass to determine obesity. The impact of sarcopenic obesity remained statistically significant after addition of well-known cardiovascular risk factors including HDL cholesterol, HbA1c, eGFR and history of CVD in the multivariate models. On the other hand, sarcopenic obesity classified according to markers for total adiposity (%BF or BMI) was not associated with CVD event.

### Table 3 Hazard ratios of incident cardiovascular disease in the categories of body composition classified using A/G ratio

|                     | HR     | (95% CI) | p value |
|---------------------|--------|----------|---------|
| **Univariate model**|        |          |         |
| Normal (reference)  | 1.00   | –        | –       |
| Sarcopenia          | 1.43   | (0.58–3.52) | 0.439 |
| Obesity             | 1.56   | (0.71–3.43) | 0.269 |
| Sarcopenic obesity  | 4.50   | (1.93–10.46) | 0.006 |
| **Multivariate model**|     |          |         |
| Normal (reference)  | 1.00   | –        | –       |
| Sarcopenia          | 1.88   | (0.75–4.74) | 0.179 |
| Obesity             | 0.98   | (0.44–2.21) | 0.969 |
| Sarcopenic obesity  | 2.63   | (1.10–6.28) | 0.030 |
| HDL cholesterol (mmol/l) | 0.21 | (0.08–0.56) | 0.002 |
| HbA1c (%)           | 1.28   | (1.09–1.49) | 0.002 |
| eGFR (ml/min/1.73 m²) | 0.97 | (0.96–0.98) | < 0.001 |
| ACEIs or ARBs       | 2.07   | (1.11–3.86) | 0.022 |
| DPP4 inhibitors     | 0.46   | (0.23–0.91) | 0.025 |
| History of CVD      | 2.85   | (1.57–5.18) | 0.001 |
| **Gender-adjusted multivariate model**|     |          |         |
| Normal (reference)  | 1.00   | –        | –       |
| Sarcopenia          | 1.46   | (0.57–3.74) | 0.429 |
| Obesity             | 0.94   | (0.42–2.10) | 0.870 |
| Sarcopenic obesity  | 2.14   | (0.88–5.21) | 0.093 |
| HDL cholesterol (mmol/l) | 0.23 | (0.09–0.62) | 0.003 |
| HbA1c (%)           | 1.28   | (1.10–1.49) | 0.001 |
| eGFR (ml/min/1.73 m²) | 0.97 | (0.96–0.96) | < 0.001 |
| ACEIs or ARBs       | 2.18   | (1.17–4.10) | 0.014 |
| DPP4 inhibitors     | 0.46   | (0.23–0.88) | 0.020 |
| History of CVD      | 2.65   | (1.44–4.87) | 0.001 |
| Gender (male = 1)   | 1.67   | (0.87–3.20) | 0.126 |

ACEIs, angiotensin converting enzyme inhibitors; ARBs, angiotensin receptor blockers; CVD, cardiovascular disease; DPP4, dipeptidyl peptidase 4; CI, confidence interval; eGFR, estimated glomerular filtration rate; HDL, high-density lipoprotein; HR, hazard ratio

**Discussion**

The present study firstly demonstrated that sarcopenic obesity assessed by the whole body DXA is an independent risk factor for CVD event in patients with type 2 diabetes, when using A/G ratio or android fat mass to determine obesity. The impact of sarcopenic obesity remained statistically significant after addition of well-known cardiovascular risk factors including HDL cholesterol, HbA1c, eGFR and history of CVD in the multivariate models. On the other hand, sarcopenic obesity classified according to markers for total adiposity (%BF or BMI) was not associated with CVD event. Besides obesity, sarcopenia was reported to be associated with an increased risk for CVD. A recent large-scale population-based study revealed that sarcopenic subjects have increased CVD risks compared to the non-sarcopenic subjects [32]. Furthermore, the study demonstrated that non-sarcopenic subjects with higher diet-induced acid load, which was independently associated with increased risk of CVD, had lower CVD risk than sarcopenic subjects with lower diet-induced acid load. Hence, it is conceivable that sarcopenia could be associated with CVD risk as well as obesity, and individuals with sarcopenic obesity had a significantly higher risk of CVD. Currently, a large number of studies have been carried out to investigate the association sarcopenic obesity and cardiovascular risk factors. Several cross-sectional studies from Korea revealed that sarcopenic obesity is associated with an increased risk for hypertension [33], dyslipidemia [34], insulin resistance [13], and metabolic syndrome [35] compared with sarcopenia or obesity alone. Furthermore, in a large cross-sectional analysis of 14,528 subjects from the National Health and Nutrition Examination Survey III reported that individuals with sarcopenic obesity had the highest risk of adverse glucose metabolism [12]. Nevertheless, the longitudinal association between sarcopenic obesity and CVD event has been surveyed in only a few studies. In the prospective survey of 3366 community-dwelling older men and women, sarcopenic obesity evaluated using waist circumference (WC) and muscle strength was associated with the highest risk of CVD event [36]. On the other hand, the prospective survey of 4252 older men from the British Regional Heart Study showed that the risk of CVD events was not significantly greater in the sarcopenic obese group defined using WC and midarm muscle circumference [37]. The inconsistencies of the two longitudinal studies in the associations between sarcopenic obesity and CVD event may be partially explained by the heterogeneity in the definition and classification of sarcopenic obesity. Indeed, Kwon YN reported that the prevalence of SO varies from 0 to 48% in the previous studies depending on the background of the studied population, parameters, and cut-off values [38]. Therefore, definition of sarcopenic obesity which is useful for predicting incident CVD needs to be established. Regarding obesity, WC is generally used to evaluate the visceral fat mass as an indirect measure, however, WC was reported to be impossible to differentiate between visceral and subcutaneous fat depots [39]. Actually, Mahabadi et al. reported that visceral fat tissue measured by CT is significantly associated with CVD even after adjusted for
### SUMMARY

**Univariate model**

|                     | A/G ratio | Android fat mass | Body fat (%) | BMI          |
|---------------------|-----------|------------------|--------------|--------------|
| Normal              | 1.00(ref) | 1.00(ref)        | 1.00(ref)    | 1.00(ref)    |
| Sarcopenia          | 1.43(0.58-3.52) | 1.87(0.77-4.51) | 1.56(0.74-3.27) | 2.48(1.04-5.88) |
| Obesity             | 1.56(0.71-3.43) | 1.59(0.71-3.60) | 0.86(0.41-1.78) | 1.61(0.68-3.78) |
| Sarcopenic Obesity  | 4.50(1.93-10.46) | 3.84(1.54-9.58) | 1.86(0.79-4.37) | 2.92(0.85-10.0) |

**Multivariate model**

|                     | A/G ratio | Android fat mass | Body fat (%) | BMI          |
|---------------------|-----------|------------------|--------------|--------------|
| Normal              | 1.00(ref) | 1.00(ref)        | 1.00(ref)    | 1.00(ref)    |
| Sarcopenia          | 1.88(0.75-4.74) | 2.42(0.99-5.93) | 1.83(0.85-3.92) | 2.21(0.92-5.30) |
| Obesity             | 0.98(0.44-2.21) | 1.19(0.52-2.68) | 0.68(0.33-1.43) | 0.92(0.36-2.18) |
| Sarcopenic Obesity  | 2.63(1.10-6.28) | 2.57(1.01-6.54) | 1.67(0.69-4.02) | 1.55(0.44-5.49) |
the covariates including BMI and WC, indicating the inaccuracy of WC for the measurement of visceral adiposity to estimate future CVD events [40]. In addition, we previously demonstrated that the ratio of abdominal visceral-to-subcutaneous fat area measured by a dual bioelectrical impedance analyzer independently of cardiovascular risk factors can predict CVD events in patients with type 2 diabetes [6]. To overcome the defect of WC, a body shape index (ABSI) has been recently developed as a new anthropometric parameter based on WC, BMI and height for the assessment of visceral adiposity [41]. ABSI was reported to be able to better predict mortality than WC, and we previously demonstrated that not WC but ABSI is independently associated with arterial stiffness evaluated using brachial-ankle pulse wave velocity (baPWV) in patients with type 2 diabetes [42]. Furthermore, it is reported that ABSI is inversely correlated with muscle mass and may be useful for the diagnosis of sarcopenic obesity [43, 44]. However, it is uncertain whether sarcopenic obesity diagnosed using ABSI could be associated with increased cardiometabolic risks. Given these findings, it is conceivable that direct measurement of visceral fat may be much more relevant for the diagnosis of sarcopenic obesity. However, no data have been available so far on the longitudinal associations of the sarcopenic obesity assessed by the direct measurement of visceral fat with CVD events in patients with diabetes. In the present retrospective observational study, we have provided evidence for the first time that sarcopenic obesity defined by markers for visceral fat (A/G ratio or android fat mass) and SMI all of which can be obtained by the whole body DXA is useful for predicting CVD events in patients with type 2 diabetes.

Predictive ability of each indicator for total and visceral obesity in examining the relationship between sarcopenic obesity and CVD

In this study, BMI and %BF were used as measures of total adiposity, and A/G ratio and android fat mass were used as measures of visceral adiposity. Since DXA can simultaneously evaluate both regional fat and muscle mass, DXA was used in many studies to evaluate sarcopenia obesity with various indicators similarly to our study. Of the various indicators, %BF was widely used in previous reports [11, 23, 24, 45]. However, a recent study demonstrated that abdominal fat mass is strongly associated with CVD risk factors in the present study compared to total fat mass in whole body DXA examination [46]. In addition, although there is no report investigating the longitudinal association of CVD with sarcopenic obesity which is diagnosed based on the indicators obtained by DXA, a population-based prospective cohort study of 1485 participants reported that sarcopenic obesity diagnosed using SMI (measured by a bioelectrical impedance analysis) and index of abdominal obesity (high triglycerides with high waist circumference) have a high cardiovascular mortality risk [47]. This association of sarcopenic obesity with cardiovascular mortality remains unchanged after adjusted for BMI. These findings supported the hypothesis that indicators of visceral adiposity were more suitable for the diagnosis of sarcopenic obesity with the whole body DXA in prediction for CVD. In consistent with these findings, we clearly showed that indicators of visceral adiposity (i.e., A/G ratio and android fat mass) are more appropriate for the classification of sarcopenic obesity than indicators of total adiposity (i.e., %BF and BMI) in patients with type 2 diabetes.

Limitations

The present study has several limitations. First, the follow-up period was relatively short, and the number of CVD events was small. Second, the characteristics of patients in the present study were homogenous due to hospital-based design, therefore, generalization of our findings might be limited. Third, we were unable to obtain the information on muscle strength such as hand-grip power. It has been reported that muscular strength is useful for predicting incident CVD in the diagnosis of sarcopenia obesity. Therefore, further studies are needed to investigate the association between sarcopenic obesity which is diagnosed using both muscle mass and strength and CVD. Fourth, we did not assess the change in body composition in the present study. As the body composition changes with aging or weight gain or loss, there is a possibility that the change of body composition affects the end point. Fifth, we were unable to carry out the sensitivity analysis by gender. It is well known that men store a greater amount of fat in the visceral depot. In
addition, it is reported that there are gender differences in the prevalence of CVD and the impact of risk factors including obesity on incident CVD [48, 49]. Therefore, the sensitivity analysis by gender should be done to evaluate whether sarcopenic obesity could be associated with incident CVD in both gender. However, we could not develop valid statistical models of each gender because of the small sample size and relatively small number of female patients who reached the end-point (16 female patients reached the end-point). Finally, it is to be elucidated whether sarcopenic obesity diagnosed using A/G ratio or android measured with DXA could be associated with CVD in non-diabetic populations.

Conclusions
The present data suggest that the whole body DXA is valuable in the diagnosis of sarcopenic obesity to determine the risk of CVD events when sarcopenic obesity was defined by low SMI and high visceral adiposity (A/G ratio or android fat mass) in patients with type 2 diabetes. Meanwhile, sarcopenic obesity classified with low SMI and high total adiposity (%BF or BMI) was not associated with an increased risk of CVD events.

Additional file

Additional file 1. Clinical characteristics and medications at baseline in the four categories of body composition (normal, sarcopenia, obesity, and sarcopenic obesity) classified using android fat mass, percent of body fat and body mass index. The baseline characteristics and medications in the four categories of body composition classified according to each indicator of obesity other than A/G ratio are shown in Tables S1–S5. **Tables S1, S3, S5.** The baseline characteristics when using android fat mass, percent of body fat, and body mass index for the classification of obesity, respectively. **Tables S2, S4, S6.** The medication when using android fat mass, percent of body fat, and body mass index for the classification of obesity, respectively.

Abbreviations

ACEi: angiotensin converting enzyme inhibitors; ACR: albumin-to-creatinine ratio; A/G: android to glyoad; ALT: alanine transaminase; ARBs: angiotensin receptor blockers; AST: aspartate transaminase; %BF: percentage of body fat; BMI: body mass index; CBGs: calcium channel blockers; CT: computed tomography; CVD: cardiovascular disease; DBP: diastolic blood pressure; DPP4: dipeptidyl peptidase 4; eGFR: estimated glomerular filtration ratio; DXA: dual-energy X-ray absorptiometry; EPA: eicosapentaenoic acid; GI: glycemic index; GLP1-RA: glucagon-like peptide-1 receptors agonist; GTP: glutamyl transpeptidase; HDL: high-density lipoprotein; HRs: hazard ratios; IQR: interquartile range; JDS: Japan Diabetes Society; LDL: low-density lipoprotein; PDR: proliferative diabetic retinopathy; SBP: systolic blood pressure; SD: standard deviation; SGLT2: sodium-glucose cotransporter 2; SMI: skeletal muscle index; T2D: type 2 diabetes; TQD: thiazolidinediones; UA: uric acid; VFA: visceral fat area; WC: waist circumference; γ-GTP: gamma-glutamyl transpeptidase.

Authors’ contributions
TF designed the study, researched data, and wrote and edited the manuscript. RB, TT, KT, IM, TY, and YO contributed to intellectual discussion and reviewed and edited the manuscript. TF, RB, TT, KT, and JM researched data. As the corresponding author and guarantor of this manuscript, RB is the guarantor of this work and, as such, had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. All authors read and approved the final manuscript.

Author details
1 Department of Molecular Endocrinology and Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, 1-5-45 Yushima, Bunkyo-ku, Tokyo 113-8510, Japan. 2 Department of Diabetes, Endocrinology and Metabolism, National Center for Global Health and Medicine, Tokyo, Japan. 3 Diabetes and Metabolism Information Center, National Center for Global Health and Medicine, Tokyo, Japan. 4 Department of Medicine and Bioregulatory Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan. 5 Department of Molecular and Cellular Metabolism, Graduate School of Medical and Dental Sciences, Tokyo Medical and Dental University, Tokyo, Japan.

Acknowledgements
The authors thank all the staff of Department of Molecular Endocrinology and Metabolism, Tokyo Medical and Dental University for their contributions.

Competing interests
The authors declare that they have no competing interests.

Availability of data and materials
The datasets used and analyzed during the current study are available from the corresponding author on reasonable request.

Consent for publication
Not applicable.

Ethics approval and consent to participate
Informed consent was waived due to retrospective design of the study. The Institutional Review Board (IRB) at Tokyo Medical and Dental University approved this study (No. M2017-260).

Funding
No funding to declare.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Received: 2 March 2018 Accepted: 4 April 2018
Published online: 10 April 2018

References
1. Zalesin KC, Franklin BA, Miller WM, Peterson ED, McCullough PA. Impact of obesity on cardiovascular disease. Med Clin North Am. 2011;95:919–37.
2. Chiba Y, Saitoh S, Takagi S, Ohnishi H, Katoh N, Ohata J, Nakagawa M, Shimamoto K. Relationship between visceral fat and cardiovascular disease risk factors: the Tanno and Sobetsu study. Hypertens Res. 2007;30:229–36.
3. Canoy D, Boekholdt SM, Wareham N, Luben R, Welch A, Bingham S, Buchan L, Day N, Khaw KT. Body fat distribution and risk of coronary heart disease in men and women in the European Prospective Investigation Into Cancer and Nutrition in Norfolk cohort: a population-based prospective study. Circulation. 2007;116:2933–43.
4. Sahakyan KR, Somers VK, Rodriguez-Escudero JP, Hodge DO, Carter RE, Sochor O, Coutinho T, Jensen MD, Roger VL, Singh P, Lopez-Jimenez F. Normal-weight central obesity: implications for total and cardiovascular mortality. Ann Intern Med. 2015;163:827–35.
5. Britton KA, Massaro JM, Murabito JM, Kriere BE, Hoffmann U, Fox CS. Body fat distribution, incident cardiovascular disease, cancer, and all-cause mortality. J Am Coll Cardiol. 2013;62:921–5.
6. Fukuda T, Bouchi R, Takeuchi T, Nakano Y, Murakami M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Ratio of visceral-to-subcutaneous fat area predicts cardiovascular events in patients with type 2 diabetes. J Diabetes Investig. 2018;9:396–402.
7. Matheus AS, Tannus LR, Cobas RA, Palma CC, Negrato CA, Gomes MB. Impact of diabetes on cardiovascular disease: an update. Int J Hypertens. 2013;2013:653789.

8. Ochi M, Kohara K, Tabara Y, Kido T, Uetani E, Ochi N, Igase M, Miki T. Arterial stiffness is associated with low thigh muscle mass in middle-aged to elderly men. Atherosclerosis. 2010;212:327–32.

9. Chin SQ, Rhee SY, Chon S, Hwang YC, Jeong IK, Oh S, Ahn KJ, Chung HY, Woo JT, Kim SW, Kim JW, Kim YS, Ahn HY. Sarcopenia is independently associated with cardiovascular disease in older Korean adults: the Korea National Health and Nutrition Examination Survey (KNHANES) from 2009–2011. PLoS ONE. 2013;8:e60019.

10. Prado CM, Wells JC, Smith SR, Stephan BC, Siervo M. Sarcopenic obesity: a critical appraisal of the current evidence. Clin Nutr. 2012;31:583–601.

11. Baumgartner RN, Wayn SJ, Waters DL, Janssen I, Gallagher D, Morley JE. Sarcopenic Obesity Study. Clin Endocrinol (Oxf). 2013;78:525–32.

12. Lim S, Kim JH, Park JS, Kim YJ, Kim KW, Lim JY, Park KS, Jung HC. Sarcopenic obesity: prevalence and association with metabolic syndrome in the Korean Longitudinal Study on Health and Aging (KLoSHA). Diabetes Care. 2010;33:1652–4.

13. Kim TN, Park MS, Lim KI, Choi HY, Yang SJ, Yoo HJ, Kang HJ, Song W, Choi H, Baik SH, Choi DS, Choi KM. Relationships between sarcopenic obesity and insulin resistance, inflammation, and vitamin D status: the Korean Sarcopenic Obesity Study. Clin Endocrinol (Oxf). 2013;78:325–32.

14. Kim TN, Park MS, Kim YJ, Lee DJ, Kim MK, Kim JM, Ko KS, Rhee BD, Won JC. Association of low muscle mass and combined low muscle mass and visceral obesity with low cardiorespiratory fitness. PLoS ONE. 2014;9:e100118.

15. Kim JH, Cho JJ, Park YS. Relationship between sarcopenic obesity and cardiovascular disease risk as estimated by the Framingham risk score. J Korean Med Sci. 2015;30:266–71.

16. Kim TN, Park MS, Ryu JY, Choi HY, Hong HC, Yoo HJ, Kang HJ, Song W, Park SW, Baik SH, Newman AB, Choi KM. Impact of visceral fat on skeletal muscle mass and vice versa in a prospective cohort study: the Korean Sarcopenic Obesity Study (KSOS). PLoS ONE. 2014;9:e115407.

17. Stenholm S, Harris TB, Rantanen T, Visser M, Kritchevsky SB, Ferrucci L. Body composition and its relationship to mortality: findings from the Health, Aging, and Body Composition Study. J Nutr. 2003;133:459–64.

18. Walton C, Lees B, Crook D, Worthington M, Godsland IF, Stevenson JC. Body mass, waist circumference, and visceral obesity with low cardiorespiratory fitness. BMJ Open Diabetes Res Care. 2016;4:e000188.

19. Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of sarcopenia and visceral obesity with low cardiorespiratory fitness. Circ J. 2002;66:987–92.

20. Han E, Kim G, Hong N, Lee YH, Kim DW, Shin HJ, Lee BW, Kang ES, Lee IK, Cha BS. Association between dietary acid load and the risk of cardiovascular disease: nationwide surveys (KNHANES 2008–2011). Cardiovasc Diabetol. 2016;15:122.

21. Araki E, Ito C, Inagaki N, Iwamoto Y, Kasuga M, Hanafusa T, Haneda M, Terasaka K, Hori Y, Numasawa M, Minami I, Izumiyama H, Hashimoto K, Yoshimoto T, Ogawa Y. Clinical relevance of dual-energy X-ray absorptiometry (DXA) as a simultaneous evaluation of fatty liver disease and atherosclerosis in patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15:64.

22. Bouchi R, Nakano Y, Ohara N, Takeuchi T, Murakami M, Asakawa M, Sasa-hara Y, Numasawa M, Minami I, Iuzumiya H, Hashimoto K, Yoshimoto T, Ogawa Y. Indirect measure of visceral adiposity ‘A Body Shape Index’ (ABSI) is associated with arterial stiffness in patients with type 2 diabetes. Diabetes Care. 2009;32:1993–7.

23. Shuster A, Patlas M, Pinthus JH, Mourtzakis M. The clinical importance of sarcopenia and visceral obesity with low cardiorespiratory fitness. Br J Radiol. 2012;85:1–10.

24. Albanesi CV, Dessel E, Gennant HK. Clinical applications of body composition measurements using DXA. J Clin Densitom. 2003;6:75–85.

25. Bouchi R, Nakano Y, Ohara N, Takeuchi T, Murakami M, Asakawa M, Sasa-hara Y, Numasawa M, Minami I, Iuzumiya H, Hashimoto K, Yoshimoto T, Ogawa Y. Indirect measure of visceral adiposity ‘A Body Shape Index’ (ABSI) is associated with arterial stiffness in patients with type 2 diabetes. Cardiovasc Diabetol. 2016;15:64.

26. Collaborators developing the Japanese equation for estimated GFR. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.

27. Kang SM, Yoon JW, Ahn HY, et al. Android fat depot is more closely associated with metabolic syndrome than abdominal visceral fat in elderly people. PLoS ONE. 2011;6:e27694.

28. Chen LK, Liu LK, Woo J, et al. Sarcopenia in Asia: consensus report of the Asian Working Group for Sarcopenia. J Am Med Dir Assoc. 2014;15:95–101.

29. Walton C, Lees B, Cook J, Worthington M, Goddland IF, Stevenson JC. Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age. Am J Med. 1995;99:459–64.

30. Fu X, Song A, Zhou Y, Ma X, Jiao J, Yang M, Zhu S. Association of regional body fat with metabolic risks in Chinese women. Public Health Nutr. 2014;17:2156–21.

31. Examination Committee of Criteria for ‘Obesity Disease’ in Japan. Society for the study of obesity. New criteria for ‘obesity disease’ in Japan. Circ J. 2002;66:987–92.

32. Han E, Kim G, Hong N, Lee YH, Kim DW, Shin HJ, Lee BW, Kang ES, Lee IK, Cha BS. Association between dietary acid load and the risk of cardiovascular disease: nationwide surveys (KNHANES 2008–2011). Cardiovasc Diabetol. 2016;15:122.

33. Park JS, Park JH, Song PS, Kim DK, Kim RH, Seol SH, Kim HK, Jung JJ, Lee JG, Park HY, Park J, Shin KJ, Kim DJ, Moon YS. Sarcopenic obesity as an independent risk factor of hypertension. J Am Soc Hypertens. 2013;7:420–5.

34. Baek SJ, Nam GE, Han KD, Choi SW, Jung SW, Bok AR, Kim YH, Lee KS, Han BD, Kim DH. Sarcopenia and sarcopenic obesity and their association with dyslipidemia in Korean elderly men: the 2008–2010 Korea National Health and Nutrition Examination Survey. J Endocrinol Invest. 2014;37:247–60.

35. Chung JY, Kang HT, Lee DC, Lee HR, Lee YJ. Body composition and its association with cardiometabolic risk factors in the elderly: a focus on sarcopenic obesity. Arch Gerontol Geriatr. 2015;56:270–8.

36. Stephen WC, Janssen I. Sarcopenic-obesity and cardiovascular disease risk in the elderly. J Nutr Health Aging. 2009;13:460–6.

37. Atkins Jl, Whincup PH, Morris RW, Lennon LT, Papacosta O, Wannamethee SG. Sarcopenic Obesity and Risk of Cardiovascular Disease and Mortality: A Population-based Cohort Study of Older Men. J Am Geriatr Soc. 2014;62:253–60.

38. Krawka NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE. 2012;7:e39504.

39. Krawka NY, Krakauer JC. A new body shape index predicts mortality hazard independently of body mass index. PLoS ONE. 2012;7:e39504.

40. Biolo G, Di Girolamo FG, Breglia A, Chiuc M, Baglio V, Vinci P, Toigo G, Lucchinelli M, Mazzucco S, Situlin R. Inverse relationship between ‘a body shape index’ (ABSI) and fat-free mass in a Caucasian population. J Nutr. 2015;145:2690–7.

41. Krakauer NY, Krakauer JC. Relationship between “a body shape index” (ABSI) and body fat with metabolic risks in Chinese women. Public Health Nutr. 2015;18:454–60.

42. Walton C, Lees B, Cook J, Worthington M, Goddland IF, Stevenson JC. Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age. Am J Med. 1995;99:459–64.

43. Gomez-Peralta F, Abreu C, Cruz-Bravo M, Alcarria E, Gutierrez-Buey G, Moreno H, Baik SH, Choi DS, Choi KM. Relationships between sarcopenic obesity on cardiovascular disease risk factors in obese postmenopausal women. Obesity (Silver Spring). 2006;14:2277–83.

44. Walton C, Lees B, Cook J, Worthington M, Goddland IF, Stevenson JC. Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age. Am J Med. 1995;99:459–64.

45. Walton C, Lees B, Cook J, Worthington M, Goddland IF, Stevenson JC. Body fat distribution, rather than overall adiposity, influences serum lipids and lipoproteins in healthy men independently of age. Am J Med. 1995;99:459–64.
46. Wiklund P, Toss F, Weinheil L, Hallmans G, Franks PW, Nordstrom A, Nordstrom P. Abdominal and gynoid fat mass are associated with cardiovascular risk factors in men and women. J Clin Endocrinol Metab. 2008;93:4360–6.

47. Chuang SY, Hsu YY, Chen RC, Liu WL, Pan WH. Abdominal obesity and low skeletal muscle mass jointly predict total mortality and cardiovascular mortality in an elderly asian population. J Gerontol A Biol Sci Med Sci. 2016;71:1049–55.

48. Mosca L, Barrett-Connor E, Wenger NK. Sex/gender differences in cardiovascular disease prevention: what a difference a decade makes. Circulation. 2011;124:2145–54.

49. Song X, Tabak AG, Zethelius B, Yudkin JS, Söderberg S, Laastikainen T, Stehouwer CD, Dankner R, Joussilahti P, Onat A, Nilsson PM, Satman L, Vaccaro O, Tuomilehto J, Qiao Q. DECODE Study Group. Obesity attenuates gender differences in cardiovascular mortality. Cardiovasc Diabetol. 2014;13:144.